Articles

August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to...

St. Jude Medical Inc. said it plans to acquire AGA Medical Holdings Inc. for about $1.3 billion. The purchase will expand St. Jude’s cardiac device offerings with a portfolio of transcatheter...

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is a major risk factor for developing emboli leading to stroke. A new approach to preventing embolisms and stroke is...

In addition to the FDA-cleared Gore Helex and the AGA Amplatzer transcatheter devices for atrial septal defects (ASDs), there are several others in development or already cleared for use outside...

Transcatheter structural heart repair devices deployed in the cath lab have largely replaced open-heart surgery as the therapy of choice. Percutaneously deployed septal occluders make it possible...

April 2, 2009 - A device implanted in the heart using minimally invasive techniques may replace the most widely prescribed drug for stroke prevention in patients with nonvalvular atrial...

In the world of cardiologists who treat adults with congenital heart disease, the unusual is not so very unusual and the rare is fairly commonplace. Take Wendy Book, M.D., for example — this week...

For some people, a new life focus is waiting just around the corner.
For Jerry Brody, it was there for 30 years — he used to drive past Children’s Hospital & Research Center Oakland (...